![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma#:~:text=On%20May%2028%2C%202021%2C%20the,2%20(FGFR2)%20fusion%20or%20other
https://www.fiercebiotech.com/biotech/lianbio-snags-325m-ipo-slightly-bigger-than-multi-partnered-biotech-s-2020-series-a
https://endpts.com/bridgebio-grabs-a-second-priority-review-for-the-portfolio-giving-perceptive-startup-cause-to-celebrate/
http://www.globenewswire.com/news-release/2020/12/01/2137349/0/en/BridgeBio-Pharma-and-Affiliate-QED-Therapeutics-Announce-FDA-Acceptance-of-New-Drug-Application-for-Infigratinib-for-the-Treatment-of-Cholangiocarcinoma.html
https://www.globenewswire.com/news-release/2020/07/28/2068546/0/en/Ivy-Brain-Tumor-Center-and-BridgeBio-Pharma-s-QED-Therapeutics-Announce-Dosing-of-First-Patient-in-Investigator-Initiated-Phase-0-2-Clinical-Trial-of-Infigratinib-in-Recurrent-Glio.html